Ocular Therapeutix Statistics
Total Valuation
OCUL has a market cap or net worth of $1.03 billion. The enterprise value is $624.41 million.
| Market Cap | 1.03B |
| Enterprise Value | 624.41M |
Important Dates
The next estimated earnings date is Monday, August 5, 2024, after market close.
| Earnings Date | Aug 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
OCUL has 154.89 million shares outstanding. The number of shares has increased by 70.60% in one year.
| Shares Outstanding | 154.89M |
| Shares Change (YoY) | +70.60% |
| Shares Change (QoQ) | +46.29% |
| Owned by Insiders (%) | 0.78% |
| Owned by Institutions (%) | 80.59% |
| Float | 126.09M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.29 |
| Forward PS | 14.97 |
| PB Ratio | 2.54 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 10.43 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.39, with a Debt / Equity ratio of 0.18.
| Current Ratio | 21.39 |
| Quick Ratio | 21.04 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.46 |
Financial Efficiency
Return on equity (ROE) is -90.40% and return on invested capital (ROIC) is -18.96%.
| Return on Equity (ROE) | -90.40% |
| Return on Assets (ROA) | -42.90% |
| Return on Capital (ROIC) | -18.96% |
| Revenue Per Employee | $224,127 |
| Profits Per Employee | -$431,708 |
| Employee Count | 267 |
| Asset Turnover | 0.22 |
| Inventory Turnover | 2.23 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +33.60% in the last 52 weeks. The beta is 1.42, so OCUL's price volatility has been higher than the market average.
| Beta (5Y) | 1.42 |
| 52-Week Price Change | +33.60% |
| 50-Day Moving Average | 5.70 |
| 200-Day Moving Average | 5.29 |
| Relative Strength Index (RSI) | 63.31 |
| Average Volume (20 Days) | 2,872,802 |
Short Selling Information
The latest short interest is 23.37 million, so 15.09% of the outstanding shares have been sold short.
| Short Interest | 23.37M |
| Short Previous Month | 22.47M |
| Short % of Shares Out | 15.09% |
| Short % of Float | 18.54% |
| Short Ratio (days to cover) | 11.18 |
Income Statement
In the last 12 months, OCUL had revenue of $59.84 million and -$115.27 million in losses. Loss per share was -$1.25.
| Revenue | 59.84M |
| Gross Profit | 54.45M |
| Operating Income | -91.45M |
| Pretax Income | -115.27M |
| Net Income | -115.27M |
| EBITDA | -98.23M |
| EBIT | -101.65M |
| Loss Per Share | -$1.25 |
Balance Sheet
The company has $484.65 million in cash and $74.41 million in debt, giving a net cash position of $410.25 million or $2.65 per share.
| Cash & Cash Equivalents | 484.65M |
| Total Debt | 74.41M |
| Net Cash | 410.25M |
| Net Cash Per Share | $2.65 |
| Equity (Book Value) | 407.98M |
| Book Value Per Share | 2.63 |
| Working Capital | 495.53M |
Cash Flow
In the last 12 months, operating cash flow was -$84.15 million and capital expenditures -$2.96 million, giving a free cash flow of -$87.11 million.
| Operating Cash Flow | -84.15M |
| Capital Expenditures | -2.96M |
| Free Cash Flow | -87.11M |
| FCF Per Share | -$0.66 |
Margins
Gross margin is 90.99%, with operating and profit margins of -152.82% and -192.62%.
| Gross Margin | 90.99% |
| Operating Margin | -152.82% |
| Pretax Margin | -192.62% |
| Profit Margin | -192.62% |
| EBITDA Margin | -164.14% |
| EBIT Margin | -169.86% |
| FCF Margin | -145.57% |
Dividends & Yields
OCUL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -70.60% |
| Shareholder Yield | -70.60% |
| Earnings Yield | -11.14% |
| FCF Yield | -8.42% |
Analyst Forecast
The average price target for OCUL is $15.83, which is 136.98% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.83 |
| Price Target Difference | 136.98% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 41.32% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
OCUL has an Altman Z-Score of 3.35 and a Piotroski F-Score of 2.
| Altman Z-Score | 3.35 |
| Piotroski F-Score | 2 |